Weekly Investment Analysts’ Ratings Updates for IDEXX Laboratories (IDXX)

Several analysts have recently updated their ratings and price targets for IDEXX Laboratories (NASDAQ: IDXX):

• 4/28/2026 – IDEXX Laboratories had its price target lowered by UBS Group AG from $730.00 to $640.00. They now have a “neutral” rating on the stock.
• 4/27/2026 – IDEXX Laboratories had its “hold (c+)” rating reaffirmed by Weiss Ratings.
• 4/25/2026 – IDEXX Laboratories was downgraded by Wall Street Zen from “buy” to “hold”.
• 4/15/2026 – IDEXX Laboratories is now covered by Citigroup Inc.. They set a “neutral” rating and a $650.00 price target on the stock.
• 4/15/2026 – IDEXX Laboratories is now covered by Citigroup Inc.. They set a “hold” rating and a $650.00 price target on the stock.
• 3/31/2026 – IDEXX Laboratories had its price target lowered by Stifel Nicolaus from $775.00 to $675.00. They now have a “buy” rating on the stock.

Insider Buying and Selling

In other news, EVP Michael G. Erickson sold 5,371 shares of IDEXX Laboratories stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $627.38, for a total value of $3,369,657.98. Following the completion of the transaction, the executive vice president owned 12,693 shares of the company’s stock, valued at $7,963,334.34. This trade represents a 29.73% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Nimrata Hunt sold 2,693 shares of IDEXX Laboratories stock in a transaction dated Thursday, February 26th. The shares were sold at an average price of $661.54, for a total transaction of $1,781,527.22. Following the completion of the transaction, the executive vice president directly owned 19,899 shares of the company’s stock, valued at approximately $13,163,984.46. This trade represents a 11.92% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 45,957 shares of company stock worth $29,862,109. Corporate insiders own 0.79% of the company’s stock.

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.